Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03084380 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)

Start date: June 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3 scFv-41BB-CD3ΞΆ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with GPC3-positive advanced hepatocellular carcinoma (HCC).

NCT ID: NCT03082378 Recruiting - Obesity Clinical Trials

Central Obesity and Hepatocellular Carcinoma

Start date: March 1, 2017
Phase: N/A
Study type: Observational

Recurrence and metastases after microwave ablation(MWA) of hepatocellular carcinoma(HCC) are the major factors that influence the survival. Obesity has been reported was significantly correlated with increased risk of developing HCC. In this study, we will analysis the association of multiple obesity index(waist circumference,waist-hip ratio and body mass index) with the prognosis of HCC treated by MWA.

NCT ID: NCT03081637 Completed - Clinical trials for Hepatocellular Carcinoma

FLNA in HCC Patients

Start date: January 1, 2004
Phase: N/A
Study type: Observational

The risk of recurrence after hepatectomy for hepatocellular carcinoma (HCC) is very high. Having a predictive marker of early recurrence (ER) would be desirable to personalize the follow-up and possibly develop new targeted therapy. The aim of this study was to test the expression of Filamin A (FLNA) in a cohort of patients operated for HCC.

NCT ID: NCT03081377 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in HCC

Start date: April 2017
Phase: Phase 1
Study type: Interventional

Single arm, open-label to determine the safety and tolerability of galunisertib when combined with SBRT.

NCT ID: NCT03079778 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma

TACERT
Start date: January 2018
Phase: N/A
Study type: Interventional

Hypothesis: Patients with hepatocellular carcinoma (HCC) have few options if they fail or are unable to undertake surgery, transarterial chemoembolization (TACE) and/or chemotherapy. Radiation (RT) in a range of doses has been combined with TACE in several case cohort studies demonstrating safety and a dramatic improvement in survival. Clearly these trials are subject to bias due to non-randomized selection, possible lack of generalizability to Canadian patients, and heterogeneous patient populations. Objective: Therefore, there is a high priority need to investigate the addition of RT to TACE in a randomized fashion to determine if we can improve survival in this rapidly growing poor prognosis patient population that have no other options. Methodology: TACE eligible patients with HCC will be randomized to TACE alone or TACE plus radiation (TACERT). They cannot be eligible for standard treatments such as transplant and resection. Primary endpoint will be time-to-intrahepatic-progression. Secondary endpoints will be response rate (Modified RECIST criteria), overall survival, local failure, extrahepatic failure, toxicity, quality of life and economic feasibility.

NCT ID: NCT03071458 Completed - Clinical trials for HepatoCellular Carcinoma

Mutational Landscape in Hepatocellular Carcinoma

MUTHEC
Start date: January 2008
Phase: N/A
Study type: Observational

The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of circulating tumor DNA.

NCT ID: NCT03069508 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

Clemizole HCl for Subjects With Hepatocellular Carcinoma

Start date: February 13, 2017
Phase: Phase 2
Study type: Interventional

This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs. 500 mg mg) given orally TID to subjects with hepatocellular carcinoma that are either awaiting transplantation or have an unresectable lesion.

NCT ID: NCT03066557 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma

Start date: March 15, 2017
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. It is lack of effective drugs for systemic treatment of HCC. Currently, Sorafenib is the only choice approved by FDA for advanced HCC, although it prolongs the survival for less than 3 months. The treatment of advanced HCC still has a long way to go. At present, the relevant phase II and phase III clinical studies of apatinib on advanced HCC are ongoing. Based on our important discovery of previous clinical studies, we intend to enlarge the sample size and make further observation for the efficacy and safety of apatinib in patients with advanced HCC.

NCT ID: NCT03053596 Recruiting - Clinical trials for Hepatocellular Carcinoma

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Start date: November 2016
Phase: N/A
Study type: Observational

The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearls for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment.

NCT ID: NCT03048123 Completed - Clinical trials for Hepatocellular Carcinoma

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

Start date: October 1, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large and unresectable hepatocellular carcinoma staged BCLC A/B.